Current Opinion on Peritoneal Carcinomatosis Treatment: a Survey of the Indian Society of Peritoneal Surface Malignancies (ISPSM)

David Martin 1 · F. Grass 1 · S. V. S. Deo 2 · K. R. Ashwin 3 · A. Maheshwari 4 · M. Hübner 1 · S. P. Somashekhar 3

Accepted: 12 October 2020 / Published online: 19 October 2020 © The Author(s) 2020

Abstract
Purpose Patients with peritoneal carcinomatosis (PC) are increasingly treated with multidisciplinary combined approaches. The study aim was to assess current practice and perceptions of treatment modalities of PC.

Methods Indian Society of Peritoneal Surface Malignancies (ISPSM) members were invited to complete an online survey. Current practice and perceptions of treatment modalities were assessed through 19 closed questions. Scores were assessed using a Likert scale (0: not important, 5: very important). Treatment modality satisfaction was assessed using a semantic scale (frustrated: 0, perfectly happy: 10). Participants were sent 3 reminders at 4-week intervals.

Results Fifty-seven out of 182 members completed the survey (31%). Forty percent of participants had an experience of at least 10 years, and 75% stated treating less than 20 PC patients per year. Main treatment goals for patients with PC were cure (5/5) and symptom relief (4/5). Participants’ satisfaction with treatment modalities for ovarian, colorectal, and gastric PC were 6/10, 5/10, and 2/10, respectively. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian (57%) and colorectal (44%) origins were considered to be useful. Clinical usefulness of chemotherapy for gastric PC was rated to be low (17%).

Conclusions Current treatment modalities fall short to satisfy the needs (cure, symptom relief) of patients with PC. Alternative systemic and intraperitoneal treatment modalities should be assessed.

Keywords Peritoneal carcinomatosis · Treatment · Survey

Introduction
The prognosis for peritoneal carcinosis (PC) is poor and the response to systemic chemotherapy limited [1]. Intraperitoneal treatment has brought some progress, especially for ovarian cancer [2]. Several studies reporting on systemic chemotherapy and symptom-directed surgery without cytoreduction demonstrated a median survival ranging from 3 to 7 months for patients with PC from non-gynecologic malignancies [3, 4]. The combination of systemic chemotherapy after extensive cytoreductive surgery (CRS) with concurrent heated intraperitoneal chemotherapy (HIPEC) has demonstrated a remarkable improvement in survival of highly selected patients over the last two decades, with even a chance for long-term survival [5–8]. However, these procedures have high morbidity and mortality, and many patients are not eligible. Furthermore, role of HIPEC remains unclear and its effectiveness seems limited due to poor distribution and penetration of chemotherapy [9, 10].

More recently, targeted drugs and immunotherapy but also alternative intraperitoneal options such as pressurized intraperitoneal aerosol chemotherapy (PIPAC) and neoadjuvant intraperitoneal and systemic chemotherapy (NIPS) have become available. PIPAC is a novel minimal-invasive approach for intraperitoneal drug delivery. Administration as an aerosol allows for better distribution within the abdominal cavity, and tissue concentrations of the therapeutic agents are increased.
NIPS is a bidirectional chemotherapy regimen that has been developed to reduce the volume and peritoneal cancer index of PC [12]. However, specific evidence-based guidelines and consensus on optimal treatment strategy for PC are lacking and vary widely.

The aim of this study was to assess practice and perceptions regarding PC, as well as satisfaction with available treatment modalities.

**Methods**

This is a qualitative study among Indian Society of Peritoneal Surface Malignancies (ISPSM) members. The network is composed of 182 members who are involved in the care of PC. The questions concerned demographics, current practice, and perceptions concerning available treatment modalities for PC. The same survey has previously been distributed among a Swiss oncology network in 2017, and same methodology was used in the present study [13].

Treatment goals were evaluated by the participants, and overall scores were obtained depending on their rating on a Likert scale (0: not important, 5: very important). Satisfaction with treatment modalities was measured using a semantic scale (0: frustrated, 10: perfectly happy). A similar scale was used to assess new treatment needs for PC (0: no need, 10: urgent need). Usefulness of chemotherapy and HIPEC for different origins of PC was assessed with closed questions and 3 possible answers (poor, moderate, and high). Nineteen questions were included in the survey (supplementary material). An online software was used (Survey Monkey®) with email distribution. Three reminders were sent at 4-week intervals.

Numbers and percentages were used for categorial variables, while medians and interquartile ranges (IQR) were used for continuous variables.

**Results**

Fifty-seven out of 182 members completed the survey, yielding a response rate of 31%. Demographics are presented in Table 1. Most participants (n = 23, 40%) had an experience of at least 10 years and vast majority (n = 43, 75%) treated less than 20 PC patients annually. Thirty-four participants (60%) worked in centers offering HIPEC treatments, while 15 in centers offering PIPAC (26%).

Main goals for the treatment of patients with PC were cure and symptom relief (Fig. 1). The need for new treatment approaches was high (8/10, IQR 7–10). Participants’ satisfaction with treatment modalities for different PC origins is displayed in Fig. 2.

| Table 1 | Participant demographics          | Overall, n = 57 |
|---------|----------------------------------|----------------|
| Speciality                       |                   |
| Medical oncologists              | 3 (5%)           |
| Gynaecologic surgical oncologists | 25 (44%)         |
| Gastrointestinal surgical oncologists | 29 (51%)     |
| Years since board qualification * |                   |
| < 5 years                        | 22 (39%)         |
| 5–10 years                       | 12 (21%)         |
| > 10 years                       | 23 (40%)         |
| Patients with PC personally treated annually |                   |
| < 10                              | 29 (51%)         |
| 10–20                            | 18 (32%)         |
| 20–50                            | 7 (12%)          |
| > 50                             | 3 (5%)           |
| Annual number of HIPEC procedures at institution |                   |
| 0                                 | 23 (40%)         |
| < 10                              | 11 (19%)         |
| 10–20                            | 9 (16%)          |
| 20–50                            | 10 (18%)         |
| > 50                             | 4 (7%)           |

*Oncology, surgical oncology, or other specialist degree or fellowship

Usefulness of chemotherapy and HIPEC as treatments for PC of different origins is shown in Table 2. HIPEC for PC of ovarian (high; 57%) and colorectal (high; 44%) origins were considered useful, while systemic chemotherapy for gastric PC was considered not very useful (poor; 57%).

**Discussion**

This study identified cure and symptom relief as main treatment goals for patients with PC. Participant’s satisfaction with available treatment options for colorectal and gastric PC was low, and most participants expressed a need for new treatment modalities. HIPEC and systemic chemotherapy were considered most useful options for ovarian and colorectal PC, while their utility in gastric PC seemed less convincing.

The ISPSM network is a national group with quite variable experience in the treatment of PC considering patient accrual, as illustrated by the demographics of this current study. The participants were mainly surgical oncologists (95%) and majority (75%) treated less than 20 PC patients per year. A recent retrospective study on CRS/HIPEC procedures showed that postoperative morbidity could be improved through centralization in high volume centers, with a threshold of 45 cases per year [14]. Another multicentric study demonstrated that
centers with more than 7 years of experience in the treatment of PC had lower postoperative morbidity and better overall survival [15]. However, patient’s registration and surgery characteristics are specific to each country, which limits comparisons and the creation of homogeneous registers [16]. Otherwise, the vision of PC and its various treatments seems to differ between oncologic surgeons and medical oncologists [17]. Indications are controversial, which is reflected by differences in national guidelines and in the numbers of treated patients between individual hospitals, regions and countries [17]. Thus, it is essential to discuss treatment strategies in the setting of multidisciplinary team meetings as done in the vast majority of expert centers [18].

The concepts of centralization in order to increase the intermediate and high volume centers (> 30 cases/year), training the surgeons with less experience in courses and the fact of addressing the most complex procedures to expert centers have been shown to be beneficial in reducing postoperative morbidity and increasing survival in various type of cancers [19, 20]. Unfortunately, this study did not assess how participants felt about their specific training for the treatment of PC.

In the present study, main treatment goals of PC were cure and symptom relief, which is comparable to a former survey among Swiss oncologists [13]. A retrospective study reported that improved survival and preserving quality of life by reducing both disease-related symptoms and therapy-related side-effects were important treatment goals [21]. These goals were considered moderately important in this survey, which furthermore showed that the economic aspect was not important at all. A previous study on quality of life after PIPAC showed that other requirements for optimal PC treatment included oncological efficacy (tumor response, survival) but also low toxicity and few side effects [22]. These observations may reflect a gap between physicians’ expectations and the history of the disease, with cost effectiveness being questioned [13].

Usefulness of chemotherapy and HIPEC was heterogeneous in this survey. However, HIPEC and systemic chemotherapy were considered most useful for ovarian and colorectal PC, while their use in gastric PC was questioned. A recent worldwide web-based survey conducted amongst experts in 19 countries estimated that currently more than 3800 patients with PC (synchronous and metachronous) were annually treated with CRS and HIPEC in 430 centers [18]. In a randomized trial, CRS followed by HIPEC improved survival in patients with PC of colorectal origin if complete cytoreduction could be performed [23]. Eight-year follow-up of this cohort confirmed the significant increase of survival time, even with a possibility of long-term survival [6]. Another randomized study showed that CRS with intraperitoneal chemotherapy may be superior to systemic oxaliplatin-based treatment of colorectal cancer with resectable isolated peritoneal metastases [24]. Furthermore, the therapeutic approach combining CRS with perioperative intraperitoneal chemotherapy can be performed with acceptable morbidity and mortality [25].

Definite curative potential of approximately 28% has been reported in a colorectal PC cohort including 67 patients [26]. In an international survey, experts currently considered CRS and HIPEC to be a treatment with curative intent in colorectal PC [18]. In this survey, the role of CRS and HIPEC in gastric cancer was found to be questionable, although the evidences have suggested their role in patients with a low peritoneal disease burden that can be completely reduced and in
Table 2 Clinical usefulness of chemotherapy and HIPEC

|                      | Poor (%) | Moderate (%) | High (%) |
|----------------------|----------|--------------|----------|
| Systemic chemotherapy|          |              |          |
| Ovarian origin       |          |              |          |
| As second line       | 5 (7%)   | 26 (46%)     | 26 (46%) |
| As third line        | 20 (35%) | 20 (35%)     | 17 (30%) |
| Colorectal origin    |          |              |          |
| As first line        | 14 (24%) | 32 (57%)     | 11 (19%) |
| As second line       | 15 (26%) | 34 (60%)     | 8 (13%)  |
| Gastric origin       |          |              |          |
| As first line        | 32 (57%) | 15 (26%)     | 10 (17%) |
| As second line       | 38 (67%) | 14 (24%)     | 5 (9%)   |
| HIPEC                |          |              |          |
| Ovarian origin       | 5 (7%)   | 20 (36%)     | 32 (57%) |
| Colorectal origin    | 7 (12%)  | 25 (44%)     | 25 (44%) |
| Gastric origin       | 23 (40%) | 26 (45%)     | 8 (15%)  |

**HIPEC** hyperthermic intraperitoneal chemotherapy, **PC** peritoneal carcinomatosis

...bidirectional intraperitoneal/systemic chemotherapy (NIPS) has been recently developed [34–36]. Complete cytoreduction is often difficult when the peritoneal cancer index (PCI) score is high or there is extensive involvement of the small bowel mesentery. Thus, NIPS is proposed for PCI reduction, eradication of free peritoneal floating cancer cells, and pathological response before CRS [36]. New modalities might also include intraperitoneal immunotherapy, which is particularly interesting due to the wide range of immune competence of the peritoneal cavity [13, 37]. The wide variety of anticancer immunotherapeutic strategies are now garnering attention for control of regional disease of the peritoneal cavity [38].

This has several limitations that need to be addressed. The ISPSM network is a national group mainly composed of surgical oncologists which might lead to an overrepresentation of surgical treatment choices. The specialties of members who did not answer the survey are unknown, as are the reasons why they did not respond. The response rate was rather low despite 3 reminders, leading to possible selection bias. However, the response rate to this survey was higher (31%) than other previous surveys performed targeting similar networks (23-28%) [17, 39]. Concerning healthcare system, a large proportion of Indian centers do not have access or cannot afford all treatment modalities, which may have introduced selection bias. Indeed, ISPSM members who responded to the survey had varied experiences, with limited access to treatment (for example, 40% do not have the possibility of carrying out HIPEC procedures in their center); thus, this constitutes a certain heterogeneity among the cohort and limits interpretation and generalization. It should also be noted that the various specialists had access to all questions, even those outside their specialty, which potentially introduced systematic errors. Finally, due to their rarity, primary peritoneal cancers (pseudomyxoma peritonei and peritoneal mesothelioma) have not been addressed.

In conclusion, main treatment goals of PC were cure and symptom relief. Furthermore, this survey pointed out a lack of satisfaction with treatment approaches and alternative systemic and intraperitoneal modalities should be assessed.

**Authors’ Contributions** All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

**Funding** Open access funding provided by University of Lausanne.

**Compliance with Ethical Standards**

**Conflict of Interest** The authors declare that they have no conflict of interest.

**Ethics Statement** This survey targeted medical staff only and did not affect patients. The local Committee for Medical and Health Research Ethics (CER-VD) suggested that no ethical approval was required.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243(2):212–22. https://doi.org/10.1097/01.sla.0000197770.46394.16.

2. Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. Hematol Oncin Clin North Am. 2018;32(6):943–64. https://doi.org/10.1016/j.hoc.2018.07.010.

3. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545–50. https://doi.org/10.1046/j.1365-2168.2002.02274.x.

4. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63.

5. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3):263–7. https://doi.org/10.1200/jco.2011.37.1039.

6. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. https://doi.org/10.1245/s10434-008-9966-2.

7. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5. https://doi.org/10.1200/jco.2008.17.0190.

8. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ 3rd. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756–62. https://doi.org/10.1002/cncr.25116.

9. Morano WF, Khalili M, Chi DS, Bowne WB, Esquivel J. Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions—a systematic review. J Surg Oncol. 2018;117(2):245–59. https://doi.org/10.1002/jso.24813.

10. Jewell A, McMahon M, Khabele D. Heated intraperitoneal chemotherapy in the management of advanced ovarian cancer. Cancers. 2018;10(9). https://doi.org/10.3390/cancers10090296.

11. Teixeira Farinha H, Grass F, Labgaa I, Pache B, Demartines N, Hubner M. Inflammatory response and toxicity after pressurized intraperitoneal aerosol chemotherapy. J Cancer. 2018;9(1):13–20. https://doi.org/10.7150/jca.21460.

12. Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, Endou Y, et al. Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am. 2003;12(3):635–48.

13. Grass F, Martin D, Montemurro M, Mathevet P, Wolfer A, Coukos G, et al. Current opinion and knowledge on peritoneal carcinomatosis: a survey among a Swiss oncology network. Chemotherapy. 2018;63(3):143–7. https://doi.org/10.1159/000488774.

14. Noiret B, Clement G, Lenne X, Brundet A, Glehen O, Voron T, et al. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year national French practice. Ann Surg. 2020;272:847–54. https://doi.org/10.1097/sla.0000000000004326.

15. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63–8. https://doi.org/10.1200/jco.2009.23.9285.

16. Verwaal VJ, Rau B, Jamali F, Gilly FN, de Hingh I, Takala H, et al. Peritoneal carcinomatosis from colorectal origin: incidence and current treatment metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2018;44:1942–8. https://doi.org/10.1016/j.ejso.2018.07.003.

17. Vanlanten R, Lodge P, Barkun JS, Farges O, Rogiers X, Soreide K, et al. Toward a consensus on centralization in surgery. Ann Surg. 2015;20(5):928–34. https://doi.org/10.1016/j.ejso.2015.01.016.

18. Bushati M, Rovers KP, Sommariva A, Sugarbaker PH, Morris DL, Yonemura Y, et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis: experiment or standard care? A survey among oncologic surgeons and medical oncologists. Int J Clin Oncol. 2015;20(5):928–34. https://doi.org/10.1016/j.ejso.2015.01.016.

19. Vonlanthen R, Lodge P, Barkun JS, Farges O, Rogiers X, Soreide K, et al. Toward a consensus on centralization in surgery. Ann Surg. 2015;20(5):928–34. https://doi.org/10.1016/j.ejso.2015.01.016.

20. Kusamura S, Baratti D, Virzi S, Bonomi S, Iusco DR, Grassi A, et al. Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres. J Surg Oncol. 2013;107(4):312–9. https://doi.org/10.1002/jso.22321.

21. Odendahl K, Solass W, Demtroder C, Giger-Pabst U, Zieren J, Tempfer C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Eur J Surg Oncol. 2015;41(10):1379–85. https://doi.org/10.1016/j.ejso.2015.06.001.

22. Teixeira Farinha H, Grass F, Kefleyesus A, Achtari C, Romain B, Montemurro M, et al. Impact of pressurized intraperitoneal aerosol chemotherapy on quality of life and symptoms in patients with peritoneal carcinomatosis: a retrospective cohort study. Gastroenterol Res Pract. 2017;2017:4596176–10. https://doi.org/10.1155/2017/4596176.

23. Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. https://doi.org/10.1200/jco.2003.04.187.

24. Cashin PH, Mahteme H, Spang N, Syk J, Frodin JE, Torkzad M, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial. Eur J Cancer. 2016;53:155–62. https://doi.org/10.1016/j.ejca.2015.09.017.
25. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92. https://doi.org/10.1200/jco.2004.10.012.

26. Cashin PH, Dranichnikov F, Mahteme H. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy treatment of colorectal peritoneal metastases: cohort analysis of high volume disease and cure rate. J Surg Oncol. 2014;110(2):203–6. https://doi.org/10.1002/jso.23610.

27. Feingold PL, Kwong ML, Sabesan A, Sorber R, Rudloff U. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time? J Gastrointest Oncol. 2016;7(1):87–98. https://doi.org/10.3978/j.issn.2078-6891.2015.098.

28. Roviello F, Caruso S, Neri A, Marrelli D. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. Eur J Surg Oncol. 2013;39(12):1309–16. https://doi.org/10.1016/j.ejso.2013.10.010.

29. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;(1):Cd005340. https://doi.org/10.1002/14651858.CD005340.pub4.

30. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618.

31. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–7. https://doi.org/10.1245/s10434-010-1039-7.

32. Klaver CE, Groenen H, Morton DG, Laurberg S, Bemelman WA, Tanis PJ. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis. 2017;19(3):224–36. https://doi.org/10.1111/codi.13593.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.